Table 4 |
|||||
|
Performance at different cut-offs of DAS28 at week 22 for dose increase |
|||||
|
DAS cut-off |
Sensitivity |
Specificity |
PPV |
NPV |
Accuracy |
|
|
|||||
|
2.0 |
0.99 |
0.13 |
0.23 |
0.98 |
0.31 |
|
2.5 |
0.99 |
0.22 |
0.25 |
0.99 |
0.38 |
|
2.6 |
0.99 |
0.26 |
0.26 |
0.99 |
0.41 |
|
3.0 |
0.98 |
0.38 |
0.29 |
0.98 |
0.50 |
|
3.2 |
0.96 |
0.46 |
0.32 |
0.98 |
0.57 |
|
4.0 |
0.79 |
0.66 |
0.38 |
0.92 |
0.68 |
|
4.5 |
0.76 |
0.77 |
0.47 |
0.92 |
0.77 |
|
5.0 |
0.58 |
0.87 |
0.55 |
0.89 |
0.81 |
|
5.1 |
0.53 |
0.88 |
0.55 |
0.88 |
0.81 |
|
5.5 |
0.43 |
0.95 |
0.69 |
0.86 |
0.84 |
|
6.0 |
0.34 |
0.97 |
0.73 |
0.85 |
0.83 |
|
6.5 |
0.19 |
0.98 |
0.72 |
0.82 |
0.81 |
|
|
|||||
|
DAS, disease activity score; PPV, positive predictive value (predictive value to give a dose increase as a measure of insufficient response); NPV, negative predictive value (predictive value to continue on the current dose as a measure of good response); PPV, NPV and accuracy were calculated using the following formulae:
c) Accuracy = sensitivity* a_priori_chance + specificity* (1-a_priori_chance) The a priori chance is given by the percentage of patients that need a dose increase as a measure of insufficient response. |
|||||
|
Vander Cruyssen et al. Arthritis Research & Therapy 2005 7:R1063 doi:10.1186/ar1787 |
|||||
